Theravance Biopharma, Inc. (TBPH) Q2 2025 Earnings Call Transcript

Theravance Biopharma (TBPH) reported a strong Q2 2025, with YUPELRI net sales increasing 22% year-over-year to approximately $66 million, further boosted by a $7.5 million milestone from its China approval. The company significantly enhanced its financial position by completing the $225 million sale of its remaining TRELEGY royalty interest, with an additional $150 million in high-probability milestones expected from Royalty Pharma over the next 18 months. Operationally, the Phase III CYPRESS trial for ampreloxetine, targeting neurogenic orthostatic hypotension in Multiple System Atrophy (MSA nOH), is nearing open-label enrollment completion, with topline data anticipated in approximately six months, representing a potential transformative catalyst given the high unmet need and ampreloxetine's differentiated profile. TBPH ended the quarter with $340 million in cash and no debt, projecting improved non-GAAP losses and cash burn in the second half of 2025, positioning it for significant shareholder value creation.

Analysis

Theravance Biopharma reported a strong Q2 2025, demonstrating robust execution on both its commercial and development fronts. The company's commercial asset, YUPELRI, delivered net sales of $66.3 million, a 22% year-over-year increase driven by 4% demand growth and favorable net pricing; management noted that underlying growth remained in the mid-teens excluding a one-time adjustment, underscoring sustained momentum. The balance sheet was significantly fortified by the $225 million sale of its remaining TRELEGY royalty interest, resulting in a quarter-end cash position of approximately $340 million with no debt. This financial strength is further supported by the high probability of receiving an additional $150 million in milestones from Royalty Pharma within 18 months, stemming from TRELEGY's strong sales performance. The primary value driver is the late-stage asset ampreloxetine, with its Phase III CYPRESS trial for neurogenic orthostatic hypotension in MSA patients nearing open-label enrollment completion. Top-line data, expected approximately six months post-enrollment, represents a transformative catalyst for the company given the high unmet need and the drug's differentiated mechanism. With near-neutral cash burn from operations and a reaffirmed 2025 guidance, Theravance is financially well-positioned heading into this pivotal data readout.

Key Decisions for Investors

• The investment thesis for Theravance is now primarily driven by the binary outcome of the ampreloxetine CYPRESS trial, with the company's $340 million cash position and no debt providing a substantial financial runway through this key catalyst.
• Investors should monitor YUPELRI's performance for continued profit margin expansion and its ability to achieve the $250 million annual sales threshold, which would trigger a $25 million milestone payment and further de-risk the company's financial profile.
• Given the high-impact nature of the upcoming CYPRESS data, it is prudent to manage risk exposure, as a positive result could unlock significant value in the rare disease market, while a failure would materially reset the company's valuation.